Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Leritrelvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Leritrelvir is an oral antiviral tablet for COVID-19, developed in China by Guangdong Raynovent Biotech together with Guangzhou Laboratory and the Guangzhou Institute of Respiratory Health. It is sold there as 乐睿灵®. Unlike most medicines of its type, it is taken on its own, without a ritonavir booster, and a course lasts five days.
China's National Medical Products Administration (NMPA) granted it conditional approval in March 2023, and the company announced in August 2026 that this had been converted to a regular (full) approval. It is approved for adults with:
It is a prescription infection medicine and should only be taken on a doctor's advice, ideally soon after symptoms begin.
The coronavirus relies on an enzyme called the 3CL (main) protease to cut its proteins into working parts before it can copy itself. Leritrelvir blocks that enzyme and so stops the virus from multiplying. It stays attached to the enzyme for longer than earlier medicines of this kind, which is why it does not need ritonavir to keep its blood level up. That also avoids the long list of drug interactions that come with ritonavir.
The phase 3 trial, published in eClinicalMedicine, enrolled 1,359 adults aged 18 to 75 with mild or moderate COVID-19 at 29 sites in China, all treated within 48 hours of their first symptoms. Almost all (98.5%) were vaccinated. People taking leritrelvir recovered from all 11 tracked symptoms about 20 hours sooner than those on placebo (median 251 vs 271 hours). Viral load also fell faster, with an extra 0.82 log10 drop by day 4. Nobody in either group was admitted to hospital, became severely ill or died, so the trial could not test whether it prevents serious illness. The company also reports that a large real-world study found a lower risk of severe illness, including in people over 65 and those with other health conditions.
In the phase 3 trial the dose was:
One box holds 30 tablets, which matches this full 5-day course. According to the company, no dose change is needed for older adults, for mild or moderate liver impairment, or for mild, moderate or severe kidney impairment. Follow the dose your doctor prescribes and the instructions in the pack leaflet.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood fats: the most common side effects in the trial were raised triglycerides (11.7% vs 10.4% on placebo) and raised blood lipids (8.8% vs 7.7%). None of these was serious.
Overall: side effects were reported in 46.5% of people on leritrelvir and 43.5% on placebo; 32.2% and 27.7% respectively were judged possibly related to treatment. Serious events were rare (0.15% vs 0.45%), and only 0.29% stopped treatment because of side effects.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit. Because the medicine works best when started early, please contact us as soon as the doctor prescribes it.
No. It is approved in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. NPP also arranges other antiviral medicines that are not sold in India, such as Livtencity.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 30 tablets of 200 mg, enough for one full 5-day course at the trial dose. The tablets travel sealed in their original pack under temperature-controlled shipping and should be stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid doctor's prescription.
Being near our New Delhi dispatch point means a shorter wait for patients who need to start treatment early.
Doctors in Mumbai can send the prescription and test report together to speed up the document check.
Patients in Bangalore can have the tablets delivered home or to their clinic once everything is verified.
We share a quote and realistic delivery time first, so the doctor can decide whether the timing still suits the patient.
Physicians in Hyderabad can request the medicine for a named patient, especially where ritonavir-based options are unsuitable.
For Kolkata and the eastern states, deliveries are planned to arrive as fast as the import process allows.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating doctor can send us the prescription and medical details to begin the request.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
Patients in Rajasthan can receive the tablets without travelling, as long as the import is in their name.
We coordinate delivery for patients treated at public and private hospitals across Uttar Pradesh.
Patients across Kerala can have the course delivered to their home or hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
